|
|
|
By Leah Samuel
Molly Ferguson for STAT
After schools were threatened with losing their accreditation if they didn't diversify, many made progress — and learned it's about more than numbers.
Read More
|
By Ruth Hailu
JEAN-FRANCOIS MONIER/AFP/Getty Images
Scientists are relying on monkey research more than ever before. Congress wants the NIH and FDA to explain why that research is so important.
Read More
|
By Jack Turban
Alex Hogan/STAT, Adobe
Insurers' out-of-date or fraudulent lists of mental health providers — ghost networks — can prevent vulnerable individuals from getting the care they need.
Read More
|
Sponsor content by STAT Plus
In-depth biopharma, business, and policy analysis at your fingertips
Sign up for STAT Plus to receive in-depth analysis of the biotech and pharma industries, exclusive one-on-one interviews with industry pioneers, and inside intelligence from Capitol Hill. Don’t be the last to know. Subscribe today to start reading.
|
By Matthew Herper
Ruby Wallau for STAT
Targeted cancer drugs such as the ones that Array develops have been a major part of Pfizer’s research over the past decade.
Read More
|
By Matthew Herper
Akira Suemori/AP
Figuring out exactly where the lines should be between an academic scientist and an industry one is a constant negotiation.
Read More
|
|